Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with…
Full story
Read the full story at South China Morning Post ↗
Continue reading this story on South China Morning Post, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
